Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders

Pharmacological Research

Volumn 64, Issue 3, 2011, Pages 180-186

  Butterfield, D Allan ^a,b   Barone, Eugenio ^c   Mancuso, Cesare ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer disease; Pleiotropic functions; Statins; Statins as Janus molecules

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

AGE; ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CREATINE KINASE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; HUMAN; IMMUNOMODULATION; ISOPRENYLATION; LIVER FAILURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MYALGIA; MYELINATION; MYOPATHY; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; CHOLESTEROL; FATTY ACIDS, MONOUNSATURATED; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; NEURODEGENERATIVE DISEASES; PYRIMIDINES; PYRROLES; QUINOLINES; SULFONAMIDES;

EID: 79959953827     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.04.007     Document Type: Article

References (99)

1. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 2006 71 105 (Pubitemid 44301483)
2. T.P. Bersot Drug therapy for hypercholesterolemia and dyslipidemia L.B. Laurence, Goodman and Gilman's, The Pharmacological Basis of Therapeutics 2011 McGraw-Hill 877 908
3. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C
4. C.Y. Wang, P.Y. Liu, and J.K. Liao Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol Med 14 2008 37 44
5. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118 (Pubitemid 40261799)
6. D.A. Butterfield Atorvastatin and Abeta(1-40): not as simple as cholesterol reduction in brain and relevance to alzheimer disease Exp Neurol 228 2011 15 18
7. S.L. Cole, and R. Vassar Isoprenoids and Alzheimer's disease: a complex relationship Neurobiol Dis 22 2006 209 222
8. A. Cordle, J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth Mechanisms of statin-mediated inhibition of small g-protein function J Biol Chem 280 2005 34202 34209 (Pubitemid 41443145)
9. S.J. McTaggart Isoprenylated proteins Cell Mol Life Sci 63 2006 255 267 (Pubitemid 43202309)
10. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol Ther 84 1999 413 428
11. G.P. Littarru, and P. Langsjoen Coenzyme q10 and statins: biochemical and clinical implications Mitochondrion 7 Suppl. 2007 S168 S174
12. L. Marcoff, and P.D. Thompson The role of coenzyme q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237 (Pubitemid 46856819)
13. J. Greenwood, L. Steinman, and S.S. Zamvil Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Nat Rev Immunol 6 2006 358 370
14. P.J. van der Most, A.M. Dolga, I.M. Nijholt, P.G. Luiten, and U.L. Eisel Statins: mechanisms of neuroprotection Prog Neurobiol 88 2009 64 75
15. P.A. Lapchak, and M.K. Han Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a rock inhibitor but not the thrombolytic tissue plasminogen activator Brain Res 1344 2010 217 225
16. A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H.E. Gendelman, and K. Pahan Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of parkinson's disease J Neurosci 29 2009 13543 13556
17. V.E. Miron, S. Rajasekharan, A.A. Jarjour, S.S. Zamvil, T.E. Kennedy, and J.P. Antel Simvastatin regulates oligodendroglial process dynamics and survival Glia 55 2007 130 143 (Pubitemid 46036460)
18. L.R. Wagstaff, M.W. Mitton, B.M. Arvik, and P.M. Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880 (Pubitemid 36875671)
19. A.S. Paintlia, M.K. Paintlia, A.K. Singh, and I. Singh Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis Mol Pharmacol 73 2008 1381 1393 (Pubitemid 351574828)
20. M.I. Cerezo-Guisado, N. Garcia-Roman, L.J. Garcia-Marin, A. Alvarez-Barrientos, M.J. Bragado, and M.J. Lorenzo Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts Biochem J 401 2007 175 183 (Pubitemid 46114611)
21. V. Meske, F. Albert, D. Richter, J. Schwarze, and T.G. Ohm Blockade of hmg-coa reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease Eur J Neurosci 17 2003 93 102 (Pubitemid 36098879)
22. O. Nusse, and E.J. Neer Localization of g alpha 0 to growth cones in pc12 cells: role of g alpha 0 association with receptors and g beta gamma J Cell Sci 109 Pt 1 1996 221 228
23. M.S. Qiu, A.F. Pitts, T.R. Winters, and S.H. Green Ras isoprenylation is required for ras-induced but not for ngf-induced neuronal differentiation of pc12 cells J Cell Biol 115 1991 795 808 (Pubitemid 21909931)
24. S. Farah, Y. Agazie, N. Ohan, J.K. Ngsee, and X.J. Liu A rho-associated protein kinase, rokalpha, binds insulin receptor substrate-1 and modulates insulin signaling J Biol Chem 273 1998 4740 4746 (Pubitemid 28103223)
25. M. Sundaresan, Z.X. Yu, V.J. Ferrans, D.J. Sulciner, J.S. Gutkind, and K. Irani Regulation of reactive-oxygen-species generation in fibroblasts by rac1 Biochem J 318 Pt 2 1996 379 382 (Pubitemid 26305933)
26. A.S. Paintlia, M.K. Paintlia, I. Singh, R.B. Skoff, and A.K. Singh Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis Glia 57 2009 182 193
27. M.S. Weber, S. Youssef, S.E. Dunn, T. Prod'homme, O. Neuhaus, and O. Stuve Statins in the treatment of central nervous system autoimmune disease J Neuroimmunol 178 2006 140 148 (Pubitemid 44314180)
28. I. Smolders, I. Smets, O. Maier, M. vandeVen, P. Steels, and M. Ameloot Simvastatin interferes with process outgrowth and branching of oligodendrocytes J Neurosci Res 88 2010 3361 3375
29. Z. Xiang, and S.A. Reeves Simvastatin induces cell death in a mouse cerebellar slice culture (csc) model of developmental myelination Exp Neurol 215 2009 41 47
30. A. Li, S. Lv, Z. Yu, Y. Zhang, H. Ma, and H. Zhao Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in neonatal rats Neurol Res 32 2010 945 952
31. O. Maier, J. De Jonge, A. Nomden, D. Hoekstra, and W. Baron Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes Glia 57 2009 402 413
32. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, and G.M. Cole Inflammation and Alzheimer's disease Neurobiol Aging 21 2000 383 421 (Pubitemid 30349107)
33. K. Pahan, F.G. Sheikh, A.M. Namboodiri, and I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J Clin Invest 100 1997 2671 2679 (Pubitemid 28007534)
34. D. Champagne, D. Pearson, D. Dea, J. Rochford, and J. Poirier The cholesterol-lowering drug probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer's disease Neuroscience 121 2003 99 110 (Pubitemid 37297617)
35. C. Lindberg, M. Crisby, B. Winblad, and M. Schultzberg Effects of statins on microglia J Neurosci Res 82 2005 10 19 (Pubitemid 41604793)
36. J.D. Orr Statins in the spectrum of neurologic disease Curr Atheroscler Rep 10 2008 11 18 (Pubitemid 351385594)
37. T. Wallerath, D. Poleo, H. Li, and U. Forstermann Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects J Am Coll Cardiol 41 2003 471 478 (Pubitemid 36164505)
38. U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, and S. Schulz Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans Circulation 111 2005 2356 2363 (Pubitemid 40647072)
39. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors Circulation 97 1998 1129 1135 (Pubitemid 28152885)
40. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, and D.J. Lefer The hmg-coa reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
41. H. Kurinami, N. Sato, M. Shinohara, D. Takeuchi, S. Takeda, and M. Shimamura Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model Int J Mol Med 21 2008 531 537
42. X.K. Tong, N. Nicolakakis, P. Fernandes, B. Ongali, J. Brouillette, and R. Quirion Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice Neurobiol Dis 35 2009 406 414
43. R.G. Riekse, G. Li, E.C. Petrie, J.B. Leverenz, D. Vavrek, and S. Vuletic Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid J Alzheimers Dis 10 2006 399 406
44. T.C. Piermartiri, C.P. Figueiredo, D. Rial, F.S. Duarte, S.C. Bezerra, and G. Mancini Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage Exp Neurol 226 2010 274 284
45. M.P. Murphy, J. Morales, T.L. Beckett, G. Astarita, D. Piomelli, and A. Weidner Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs J Alzheimers Dis 22 2010 135 150
46. E. Barone, G. Cenini, F. Di Domenico, S. Martin, R. Sultana, and C. Mancuso Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of alzheimer disease: a novel mechanism of action Pharmacol Res 63 2011 172 180
47. E.G. Bliznakov, and D.J. Wilkins Biochemical and clinical consequences of inhibiting coenzyme q(10) biosynthesis by lipid-lowering hmg-coa reductase inhibitors (statins): a critical overview Adv Ther 15 1998 218 228 (Pubitemid 28454901)
48. P.H. Langsjoen, J.O. Langsjoen, A.M. Langsjoen, and L.A. Lucas Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation Biofactors 25 2005 147 152 (Pubitemid 44070842)
49. R.A. Parker, Q. Huang, and B. Tesfamariam Influence of 3-hydroxy-3-methylglutaryl-coa (hmg-coa) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature Atherosclerosis 169 2003 19 29 (Pubitemid 36830920)
50. J. Vaya, and H.M. Schipper Oxysterols, cholesterol homeostasis, and alzheimer disease J Neurochem 102 2007 1727 1737 (Pubitemid 47329280)
51. J.H. Han, Y.J. Kim, E.S. Han, and C.S. Lee Prevention of 7-ketocholesterol-induced mitochondrial damage and cell death by calmodulin inhibition Brain Res 1137 2007 11 19 (Pubitemid 46240061)
52. S.R. Panini, L. Yang, A.E. Rusinol, M.S. Sinensky, J.V. Bonventre, and C.C. Leslie Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized ldl/oxysterol J Lipid Res 42 2001 1678 1686 (Pubitemid 33020101)
53. A. Trousson, S. Bernard, P.X. Petit, P. Liere, A. Pianos, and K. El Hadri 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase a2 type iia via lxr beta and pxr J Neurochem 109 2009 945 958
54. M. Arca, S. Natoli, F. Micheletta, S. Riggi, E. Di Angelantonio, and A. Montali Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy Free Radic Biol Med 42 2007 698 705 (Pubitemid 46205153)
55. K. Kathir, J.M. Dennis, K.D. Croft, T.A. Mori, A.K. Lau, and M.R. Adams Equivalent lipid oxidation profiles in advanced atherosclerotic lesions of carotid endarterectomy plaques obtained from symptomatic type 2 diabetic and nondiabetic subjects Free Radic Biol Med 49 2010 481 486
56. H. Larsson, Y. Bottiger, L. Iuliano, and U. Diczfalusy In vivo interconversion of 7beta-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress Free Radic Biol Med 43 2007 695 701 (Pubitemid 47102124)
57. A. Berthier, S. Lemaire-Ewing, C. Prunet, S. Monier, A. Athias, and G. Bessede Involvement of a calcium-dependent dephosphorylation of bad associated with the localization of trpc-1 within lipid rafts in 7-ketocholesterol-induced Thp-1 cell apoptosis Cell Death Differ 11 2004 897 905 (Pubitemid 39139748)
58. B.S. Kumar, B.C. Chung, Y.J. Lee, H.J. Yi, B.H. Lee, and B.H. Jung A GC/MS-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats Anal Biochem 2010
59. K.M. Thelen, R. Laaksonen, H. Paiva, T. Lehtimaki, and D. Lutjohann High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels J Clin Pharmacol 46 2006 812 816 (Pubitemid 43882805)
60. M.A. Beydoun, L.L. Beason-Held, M.H. Kitner-Triolo, H.A. Beydoun, L. Ferrucci, and S.M. Resnick Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment J Epidemiol Community Health 2010
61. G. Li, J.B. Shofer, I.C. Rhew, W.A. Kukull, E.R. Peskind, and W. McCormick Age-varying association between statin use and incident Alzheimer's disease J Am Geriatr Soc 58 2010 1311 1317
62. L. Smeeth, I. Douglas, A.J. Hall, R. Hubbard, and S. Evans Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials Br J Clin Pharmacol 67 2009 99 109
63. M.D. Haag, A. Hofman, P.J. Koudstaal, B.H. Stricker, and M.M. Breteler Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study J Neurol Neurosurg Psychiatry 80 2009 13 17
64. H.T. Horsdal, A.V. Olesen, C. Gasse, H.T. Sorensen, R.C. Green, and S.P. Johnsen Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study Alzheimer Dis Assoc Disord 23 2009 18 22
65. H. Rosenberg, and D. Allard Women and statin use: a women's health advocacy perspective Scand Cardiovasc J 42 2008 268 273
66. D.L. Sparks, R.J. Kryscio, M.N. Sabbagh, D.J. Connor, L.M. Sparks, and C. Liebsack Reduced risk of incident AD with elective statin use in a clinical trial cohort Curr Alzheimer Res 5 2008 416 421
67. C. Cramer, M.N. Haan, S. Galea, K.M. Langa, and J.D. Kalbfleisch Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Neurology 71 2008 344 350
68. J. Benito-Leon, E.D. Louis, S. Vega, and F. Bermejo-Pareja Statins and cognitive functioning in the elderly: a population-based study J Alzheimers Dis 21 2010 95 102
69. J. Hippisley-Cox, and C. Coupland Unintended effects of statins in men and women in england and wales: population based cohort study using the qresearch database BMJ 340 2010 c2197
70. D.L. Sparks, R.J. Kryscio, D.J. Connor, M.N. Sabbagh, L.M. Sparks, and Y. Lin Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort Neurodegener Dis 7 2010 183 186
71. S. Trompet, P. van Vliet, A.J. de Craen, J. Jolles, B.M. Buckley, and M.B. Murphy Pravastatin and cognitive function in the elderly. Results of the prosper study J Neurol 257 2010 85 90
72. J. Shepherd, G.J. Blauw, M.B. Murphy, S.M. Cobbe, E.L. Bollen, and B.M. Buckley The design of a prospective study of pravastatin in the elderly at risk (prosper). Prosper study group. Prospective study of pravastatin in the elderly at risk Am J Cardiol 84 1999 1192 1197 (Pubitemid 29507501)
73. H.H. Feldman, R.S. Doody, M. Kivipelto, D.L. Sparks, D.D. Waters, and R.W. Jones Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: leade Neurology 74 2010 956 964
74. D.D. Waters Exploring new indications for statins beyond atherosclerosis: successes and setbacks J Cardiol 55 2010 155 162
75. D.L. Sparks, M. Sabbagh, D. Connor, H. Soares, J. Lopez, and G. Stankovic Statin therapy in Alzheimer's disease Acta Neurol Scand Suppl 185 2006 78 86 (Pubitemid 44015229)
76. D.L. Sparks, D.J. Connor, M.N. Sabbagh, R.B. Petersen, J. Lopez, and P. Browne Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the alzheimer's disease cholesterol-lowering treatment (adclt) trial Acta Neurol Scand Suppl 185 2006 3 7 (Pubitemid 44015218)
77. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, and P. Passmore Statins for the treatment of dementia Cochrane Database Syst Rev 2010 CD007514
78. J.T. O'Brien, and A. Burns Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the british association for psychopharmacology J Psychopharmacol 2010
79. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N Engl J Med 362 2010 329 344
80. R. Mayeux Clinical practice. Early Alzheimer's disease N Engl J Med 362 2010 2194 2201
81. M. Simons, F. Schwarzler, D. Lutjohann, K. von Bergmann, K. Beyreuther, and J. Dichgans Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann Neurol 52 2002 346 350 (Pubitemid 35001502)
82. G. Saher, B. Brugger, C. Lappe-Siefke, W. Mobius, R. Tozawa, and M.C. Wehr High cholesterol level is essential for myelin membrane growth Nat Neurosci 8 2005 468 475 (Pubitemid 41007564)
83. E.M. Reiman, K. Chen, J.B. Langbaum, W. Lee, C. Reschke, and D. Bandy Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging Neuroimage 49 2010 169 176
84. A.C. Fonseca, R. Resende, C.R. Oliveira, and C.M. Pereira Cholesterol and statins in Alzheimer's disease: current controversies Exp Neurol 223 2010 282 293
85. B. McGuinness, D. Craig, R. Bullock, and P. Passmore Statins for the prevention of dementia Cochrane Database Syst Rev 2009 CD003160
86. K. Hoglund, O. Wiklund, H. Vanderstichele, O. Eikenberg, E. Vanmechelen, and K. Blennow Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins Arch Neurol 61 2004 333 337 (Pubitemid 38327348)
87. B.A. Evans, J.E. Evans, S.P. Baker, K. Kane, J. Swearer, and D. Hinerfeld Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease Dement Geriatr Cogn Disord 27 2009 519 524
88. M.W. Jann, K.L. Shirley, and G.W. Small Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors Clin Pharmacokinet 41 2002 719 739 (Pubitemid 34948194)
89. J. Kiani, and S.Z. Imam Medicinal importance of grapefruit juice and its interaction with various drugs Nutr J 6 2007 33
90. A.L. Stump, T. Mayo, and A. Blum Management of grapefruit-drug interactions Am Fam Physician 74 2006 605 608 (Pubitemid 44273944)
91. J.T. Hare, and D.P. Elliott Grapefruit juice and potential drug interactions Consult Pharm 18 2003 466 472 (Pubitemid 38186006)
92. J.P. Dreier, and M. Endres Statin-associated rhabdomyolysis triggered by grapefruit consumption Neurology 62 2004 670 (Pubitemid 38252822)
93. J.P. Werba, M. Giroli, V. Cavalca, M.C. Nava, E. Tremoli, and L. Dal Bo The effect of green tea on simvastatin tolerability Ann Intern Med 149 2008 286 287
94. M. Perluigi, R. Sultana, G. Cenini, F. Di Domenico, M. Memo, and W.M. Pierce Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis Proteomics Clin Appl 3 2009 682 693
95. R. Sultana, M. Perluigi, S.F. Newman, W.M. Pierce, C. Cini, and R. Coccia Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease Antioxid Redox Signal 12 2010 327 336
96. R. Sultana, M. Perluigi, and D.A. Butterfield Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of ad: role of Abeta in pathogenesis Acta Neuropathol 118 2009 131 150
97. D.A. Butterfield, J. Drake, C. Pocernich, and A. Castegna Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide Trends Mol Med 7 2001 548 554 (Pubitemid 33127140)
98. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
99. R.Y. Mukhtar, J. Reid, and J.P. Reckless Pitavastatin Int J Clin Pract 59 2005 239 252 (Pubitemid 40331227)